Before taking Vonjo(Pacritinib)

VONJO carries several important warnings that necessitate careful patient monitoring and management before and during therapy.

Before taking Vonjo(Pacritinib)

Key precautions include the risk of serious and fatal hemorrhage, particularly in patients with low platelet counts, requiring treatment interruption before surgical procedures. Significant diarrhea must be proactively managed with anti-diarrheal agents and fluid replacement. Regular monitoring of platelet counts and electrocardiograms is essential due to risks of thrombocytopenia and QT prolongation. Concomitant use of strong CYP3A4 inhibitors or inducers is contraindicated. Caution is advised regarding potential increased risks of major cardiovascular events, thrombosis, secondary malignancies, and serious infections.

Related Columns

Pacritinib(Vonjo)

Treatment of intermediate or high-risk primary or secondary myelofibrosis in...

WeChat Scan
Free Inquiry

Dietary precautions for patients with Pacritinib

During oral treatment with pacritinib, diet is closely related to the method of administration, gastrointestinal reactions, and concomitant medications. Patients should pay attention to the following ...

Special population use of Pacritinib

Pacritinib is used in adult patients with myelofibrosis and a platelet count below 50×10⁹/L. For use in special populations, attention should focus on hepatic function, renal function, pregnancy, lact...

Precautions for Pacritinib (Vonjo) Administration

Pacritinib (Vonjo) is a kinase inhibitor indicated for the treatment of intermediate- or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis in pati...